文献速递药物相互作用治疗药物监测与药物基因组学

沃诺拉赞与埃索美拉唑对氯吡格雷或普拉格雷抗血小板功能影响的比较研究:基于CYP2C19基因型

Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.
PubMed 文献 · Clin Pharmacol Ther · 2017-10-13

在31名健康日本志愿者中比较沃诺拉赞与埃索美拉唑对氯吡格雷或普拉格雷抗血小板功能的影响。沃诺拉赞比埃索美拉唑更强烈地降低氯吡格雷和普拉格雷的血小板聚集抑制率,且按CYP2C19基因型分层后趋势一致。埃索美拉唑不影响普拉格雷的抗血小板功能,与CYP2C19基因型无关。

要点

  • 沃诺拉赞比埃索美拉唑更显著降低氯吡格雷的抗血小板功能。
  • 沃诺拉赞也比埃索美拉唑更显著降低普拉格雷的抗血小板功能。
  • 埃索美拉唑不影响普拉格雷抗血小板功能,不受CYP2C19基因型影响。

核心结论

  • 沃诺拉赞比埃索美拉唑更强烈地减弱氯吡格雷的抗血小板功能,且按CYP2C19基因型分层后趋势一致。
  • 埃索美拉唑不影响普拉格雷的抗血小板功能,与CYP2C19基因型无关。

研究设计与样本

  • 采用P2Y12 assay比较沃诺拉赞与埃索美拉唑对氯吡格雷或普拉格雷抗血小板功能的影响。
  • 研究对象为31名健康日本志愿者,其中CYP2C19 homo-EMs 14名、hetero-EMs 9名、PMs 8名。

主要发现

  • 沃诺拉赞降低氯吡格雷的血小板聚集抑制率中位值比埃索美拉唑更显著(P < 0.001)。
  • 沃诺拉赞降低普拉格雷的血小板聚集抑制率中位值比埃索美拉唑更显著(P = 0.011)。
  • 按CYP2C19基因型分层后趋势一致:homo-EMs组P = 0.004,hetero-EMs组P = 0.033,PMs组P = 0.043。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-drug interaction between antiacid and antiplatelet agents has not been fully elucidated. Vonoprazan, a new potassium competitive acid blocker, has been available in Japan. CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole, and vonoprazan. Using a P2Y12 assay, we compared the effects of vonoprazan and esomeprazole on the antiplatelet functions of clopidogrel or prasugrel in 31 healthy Japanese volunteers (14 CYP2C19 homo-extensive (homo-EMs), nine hetero-extensive (hetero-EMs), and eight poor metabolizers (PMs)). Vonoprazan decreased the median inhibition of platelet aggregation (IPA) values of clopidogrel and prasugrel more potently than esomeprazole (P < 0.001 for clopidogrel and P = 0.011 for prasugrel). The same tendencies were observed when stratified by CYP2C19 genotype groups (P = 0.004 in homo-EMs, 0.033 in hetero-EMs, and 0.043 in PMs). Vonoprazan attenuated the antiplatelet function of clopidogrel more potently than esomeprazole. Esomeprazole did not affect that of prasugrel irrespective of CYP2C19 genotype.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kagami T, Yamade M, Suzuki T, et al. Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype. Clin Pharmacol Ther. 2017. PMID: 28875498. doi:10.1002/cpt.863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。